US0144421072 - Common Stock
ALECTOR INC
NASDAQ:ALEC (3/28/2024, 2:09:48 PM)
6.06
-0.02 (-0.33%)
Alector, Inc. operates as a clinical-stage biopharmaceutical company, which engages in pioneering of immuno-neurology. The company is headquartered in South San Francisco, California and currently employs 246 full-time employees. The company went IPO on 2019-02-07. The firm is focused on immuno-neurology, a therapeutic approach for the treatment of neurodegenerative diseases. The firm is engaged in developing therapies designed to counteract these pathologies by restoring healthy immune function to the brain. Its research and drug discovery platform leverages human genetic datasets, advanced tools in bioinformatics and imaging, and insights in neurodegeneration and immunology to identify immune system. Its clinical programs include AL001 (latozinemab), AL101, and AL002. In addition, the Company also focuses on preclinical and research programs in its pipeline for indications, including Alzheimer’s disease, Parkinson’s disease, and oncology. Its first product candidate, latozinemab, is a humanized recombinant monoclonal antibody that increases the levels of progranulin (PGRN) in the brains of frontotemporal dementia carrying a progranulin (FTD-GRN) patients.
ALECTOR INC
131 Oyster Point Blvd., Suite 600
South San Francisco CALIFORNIA 94080
P: 14152315660
CEO: Arnon Rosenthal
Employees: 246
Website: https://alector.com
The FDA has delayed making a decision on Eli Lilly's donanemab, pending an advisory committee meeting.
We're starting Wednesday with a breakdown of the biggest pre-market stock movers traders will want to keep an eye on this morning!
SOUTH SAN FRANCISCO, Calif., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering...
Alector's Q4 earnings beat expectations with a higher revenue, and the company provides guidance for collaboration and expenses in 2024.
Here you can normally see the latest stock twits on ALEC, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: